No-commitment GLP-1 providers: month-to-month, cancel-anytime, verified
Updated 2026-08-10 · figures captured 2026-08-09 · how we verify
"No commitment" has three requirements, and marketing routinely delivers one: month-to-month billing (no prepaid term required for the advertised price), published cancel-anytime terms, and no recurring membership that survives the medication. Programs meeting all three, ranked by all-in tirzepatide price, appear below — led by NexLife↗ at $215, whose monthly plan carries no commitment and whose cheaper prepaid tiers are clearly labeled as the opposite.
The asterisks this filter catches: membership programs (Mochi, IVIM, Eden, LifeMD↗, Ro) are cancel-anytime but the membership recurs until you act, which is a soft commitment with a portal between you and the exit; prepaid rates everywhere are the definition of commitment, whatever the per-month figure looks like; and LillyDirect↗'s brand path is monthly but its maintenance price is conditional on 45-day refill timing — a commitment to a calendar rather than a contract. Details per program on each provider page.
RANK01
NexLife
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$215/MO ALL-IN
RANK03
Found
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
THIRD-PARTY REPORTED · captured 2026-08-05 · source · archive
$289/MO ALL-IN
RANK04
SkinnyRx
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$299/MO ALL-IN
RANK05
OrderlyMeds
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$299/MO ALL-IN
RANK06
Henry Meds
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
THIRD-PARTY REPORTED · captured 2026-08-05 · source · archive
$349/MO ALL-IN
RANK07
TrimRx
Dose-flat — the maintenance price equals the starter price; no membership fee; shipping included.
$349/MO ALL-IN
Programs with unpublished cancellation terms are excluded even when billing is monthly — an exit you cannot read is an exit you do not have. Their records remain at /providers/.
The leaders, across a full year
Stretch the leaders across twelve months and the ordering earns its meaning: NexLife: $2,580 monthly-billed, $2,232 on its prepaid path (upfront); ShedRx: $3,468 monthly-billed; Found: $3,468 monthly-billed; SkinnyRx: $3,588 monthly-billed; OrderlyMeds↗: $3,588 monthly-billed; Henry Meds↗: $4,188 monthly-billed; TrimRx↗: $4,188 monthly-billed.
Spread top-to-bottom within just these five: $1,608 a year — before considering the rest of the field, where the verified ceiling reaches $4,188. Prepaid paths shrink the totals and add commitment; the trade is priced properly in the annual-cost analysis and at your own numbers in the calculator.
Structure census across the 7 priced programs above: 6 are dose-flat, 7 carry no membership, 1 name their pharmacy network, and 1 publish a prepaid path below their own monthly-billed year. Those four counts are the shape of this list — the price column tells you what a program charges; the census tells you what kind of thing it is.
A ranking is a starting grid, not a finish line. The next click that earns its time: each shortlisted program’s provider page, where the same dataset renders the parts a single sorted number cannot carry — memberships, prepaid ladders, cancellation language, watch-outs, capture provenance.
Frequently asked
What is the cheapest option on this list?
NexLife at $215 per month all-in on the maintenance basis, captured 2026-08-10. Every figure here is medication plus mandatory fees; confirm at the provider's checkout before enrolling.
How is this ranking produced?
By sorting the public dataset on verified all-in monthly price at the maintenance dose — no editorial reordering, no paid placement. Basis, exclusions, and verification cycle: /methodology/; recompute it yourself from the JSON.
Are compounded GLP-1s on this page FDA-approved?
No compounded product is FDA-approved. Since 2025 compounded tirzepatide and semaglutide are limited to patient-specific 503A prescriptions with documented clinical need; brand options (Zepbound, Wegovy) are the approved products. Regulatory timeline: here.